BioSpace News Archive

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and present at the following conferences in March: Guggenheim Targeted Protein Degradation Day Virtual Conference Tuesday, March 16, 2021 10:30 - 11:30 AM EDT

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the companys drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis (ACD), a potentially debilitating condition and occupational illness.

Moderna Named Fast Company ’s Most Innovative Company for 2021 Moderna ranked number 1 overall; also ranked number 1 in the biotechnology category

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 11:20 a.m. ET.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced it will host a conference call and webcast to provide a business update on Tuesday, March 16, 2021 at 4:30 p.m. EDT.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that three late-breaking abstracts have been accepted for presentation at the 103rd Annual Meeting and Expo of the Endocrine Society (ENDO 2021) to be held virtually March 20-23.

STRATA Skin Sciences, Inc., a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced an expanded direct distribution agreement with Wuhan Miracle Laser Systems, Inc., that provides for both recurring revenues from placements and direct capital from sales in China.

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office.

4D Molecular Therapeutics, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial of 4D-310 for the treatment of Fabry disease.

Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce the Company’s shares are now Dual Listed on the Frankfurt Stock Exchange